Allergy medication recalled for potential cross-contamination that could be life-threatening, FDA says

Tyunews.com – ```html

Allergy Medication Recalled for Potential Cross-Contamination Risk

Allergy Medication Recalled for Potential Life-Threatening Cross-Contamination

The U.S. Food and Drug Administration has announced a significant recall of allergy medication recalled for potential cross-contamination issues that could pose serious health risks to consumers. Unique Pharmaceutical Laboratories, a division of J.B. Chemicals & Pharmaceuticals Ltd., initiated this voluntary withdrawal after discovering that certain batches of Cetirizine Hydrochloride Tablets USP 5 mg had been contaminated with ranitidine, a commonly prescribed medication used to treat heartburn and acid reflux conditions.

This recall affects four specific production lots of the allergy medication, which are being pulled from retail shelves and consumer homes. The company made the official announcement on July 18, with the FDA posting comprehensive details about the recall later that same week. Consumers who purchased these antihistamine products should check their medication bottles immediately to determine if their specific lot numbers are included in the recall.

Understanding the Cross-Contamination Risk

The contamination presents serious dangers, particularly for people experiencing severe allergies or anaphylaxis to specific components found in ranitidine. A risk statement included with the announcement indicates that individuals with hypersensitivity to ranitidine ingredients face what officials describe as a "reasonable probability" of encountering potentially "life-threatening" complications if they consume the affected medication.

Those who consume the affected antihistamine and have adverse reactions to ranitidine could experience multiple severe symptoms. These include hypotension, dyspnea, difficulty swallowing, throat and facial edema, generalized pruritic, urticaria, and loss of consciousness. The FDA emphasizes that severe hypersensitivity reactions and anaphylaxis are among the primary concerns associated with this contamination issue.

"Unique Pharmaceutical Laboratories is voluntarily recalling four lots of Cetirizine Hydrochloride Tablets USP 5 mg to the consumer level due to cross contamination with Ranitidine," an FDA notice reads clearly.

How the Contamination Was Discovered

The issue came to light through a product complaint filed directly with the company. A pharmacy technician noticed something unusual while counting tablets during the dispensing process at a local pharmacy. The complaint specifically mentioned that some Cetirizine Hydrochloride Tablets USP 5 mg displayed red dots and appeared discolored due to multiple red colored dots on the tablets.

"Product complaint received that a pharmacy technician identifies the discrepancy while counting the tablets at the time of dispensing," reads the official announcement. "A product complaint reported about Appearance of red dot on Tablets of Cetirizine Hydrochloride Tablets USP 5 mg and some tablets are discolored (Appeared as discolored due to multiple red colored dots on tablets)."

Product Details and Consumer Action Steps

The affected medication comes packaged in HDPE bottles containing 100 tablets each, bearing the NDC number 16571-401-10. Consumers can locate complete details regarding lot numbers, expiration dates, manufacturer information, distributor data, and product design specifications through the FDA recall database online. This information helps consumers verify whether their specific bottles are part of the recall.

Unique Pharmaceutical has informed its distributor, Rising Pharma Holdings Inc., which has subsequently notified its own network of distributors and customers throughout the supply chain. The company is currently organizing the return of all recalled products from retail locations and consumer homes. ABC News has contacted Rising Pharma Holdings Inc. seeking further information about the recall timeline and consumer compensation options.

Importantly, the release states that no adverse event reports have been received by Unique Pharmaceuticals concerning this particular recall situation. Individuals experiencing adverse reactions or quality problems with the product can submit reports to the FDA's MedWatch Adverse Event Reporting program through online submission, regular mail, or fax. This proactive approach ensures that any future incidents are properly documented and addressed by regulatory authorities.

Consumers who have purchased the affected allergy medication recalled for potential cross-contamination should contact their pharmacy or retailer for instructions on returning the product. While no adverse events have been reported yet, the precautionary nature of this recall demonstrates the FDA's commitment to protecting public health. Healthcare providers may want to inform patients who regularly use cetirizine about this potential issue and recommend alternative allergy medications if needed.

```